Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India.
Dharna GuptaAshish SinghNidhi GuptaNikita MehraPankaj BahugunaVipul AggarwalManjunath Nookala KrishnamurthyPartha Sarathi RoyPankaj MalhotraSudeep GuptaLalit KumarAmal KatakiShankar PrinjaPublished in: JCO global oncology (2023)
Our findings support the current inclusion of sunitinib under India's publicly financed health insurance scheme.